NoRCoRP Assessment Clinic (NoRCoRP)

The Nottingham Recovery From COVID-19 Research Platform Assessment Clinic

The main overarching aim of this study is to build a research clinic, as part of the NoRCoRP platform covering Nottingham and Nottinghamshire to facilitate learning and research in the whole population of patients who have had COVID-19.

Study Overview

• Status: Completed
• Conditions: Covid19

Detailed Description

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2 / COVID-19) pandemic, has affected over 13 million people, and caused significant worldwide mortality and morbidity. Frequent long-term respiratory complications include persistent breathlessness and fatigue, with potential for ongoing organising pneumonia and new pulmonary fibrosis as well as thromboembolic disease. Additional features seen in at least some patients post hospital include impaired musculoskeletal function, impaired renal function, neurological impairment, cardiac dysfunction and significant psychiatric morbidity.

The majority of patients with COVID-19 were not admitted to hospital, and the longer-term consequences of infection with SARS-CoV-2 in this much larger patient group are unknown. Whilst many patients had relatively mild disease and made a good recovery, a significant number have been left with symptoms similar to those who were admitted to hospital.

In setting up a post COVID-19 respiratory review clinic, we expect to generate new findings, support studies that have already been submitted for funding, to provide a focus for further grant funding, and to provide an infrastructure to support new clinical trials. We also expect the insights gained from research using this platform to be of value for service planning in the region and beyond. We will prioritise patients who were not admitted to hospital but who have been left with significant morbidity by establishing this new General Practitioner (GP) referral research clinic.

• Study Type: Observational
• Enrollment (Actual): 254

Contacts and Locations

Study Locations

• United Kingdom
  • Nottingham, United Kingdom, NG5 1PB
    • Nottingham City Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults who have previous had a diagnosis of COVID-19 and have been referred into a post-COVID-19 respiratory outpatients clinic from primary care due to ongoing complications related to the COVID-19 diagnosis.

Description

Inclusion Criteria:

• Adults (≥18 years) referred into the post COVID-19 respiratory outpatient clinic from primary care, following a swab, imaging or strong clinical diagnosis of COVID-19
• Adults discharged from hospital with a clinical diagnosis of COVID-19 (who are not included in the PHOSP-COVID study)

Exclusion Criteria:

• Children (<18 years) referred into the post COVID-19 respiratory outpatient clinic. This clinic is only open to adults and referrals for children will not be accepted
• Adults discharged from hospital with a clinical diagnosis of COVID-19 and have been included in the PHOSP-COVID study
• Patients unable to provide informed consent by themselves

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with symptoms at presentation to the research clinic	Patient reported symptoms	September 2020 - August 2024
Short Physical Performance Battery	Assessment of functional capacity	September 2020 - August 2024
Quadricep muscle strength	Assessment of functional capacity using a handheld dynamometer	September 2020 - August 2024
Chalder's Fatigue Score	Assessment of fatigue using the Chalder 11-item fatigue questionnaire	September 2020 - August 2024
Number of participants with rehabilitation needs at presentation to clinic	Rehabilitation needs based on clinical assessment by a multidisciplinary team (musculoskeletal, cognitive and cardiopulmonary)	September 2020 - August 2024
EQ-5D-5L	Assessment of generic health status using the EQ-5D-5L questionnaire	September 2020 - August 2024
Montreal Cognitive Assessment	Assessment of cognitive state using the MoCA questionnaire	September 2020 - August 2024

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anxiety and Depression	Derived by completion of the Hospital Anxiety and Depression Scale (HADS) questionnaire	September 2020 - August 2024
Pittsburgh Sleep Quality Index	Assessment of sleep quality using the PSQI questionnaire	September 2020 - August 2024
Healthcare service needs following COVID-19 diagnosis	Monitoring of NHS records for incidence of re-presentation to primary or secondary care related to COVID-19 complications and survival.	September 2020 - August 2032
Biological markers of recovery from COVID-19	Assessment of blood taken for clinical purposes (where available) including renal function, liver function, full blood count, HbA1C, Brain natriuretic peptide, vitamin D, thyroid function, C-reactive protein (CRP), Creatine kinase for markers of COVID-19 recovery. Batched inflammatory and metabolic markers as well as whole blood DNA will also be assessed from stored samples.	September 2020 - August 2032
Fried Frailty Index	Frailty assessment covering: shrinking, exhaustion, physical activity, slowness and weakness domains.	September 2020 - August 2024
Body composition	Body composition derived from bioelectrical impedance analysis to determine: body mass index, fat free mass index, fat free mass (kg), fat mass (kg).	September 2020 - August 2024

Collaborators and Investigators

• Sponsor: Nottingham University Hospitals NHS Trust
• Investigators: Principal Investigator: Charlotte Bolton, University of Nottingham & Nottingham University Hospitals NHS Trust

Study record dates

Study Major Dates

• Study Start (Actual): December 3, 2020
• Primary Completion (Actual): August 8, 2024
• Study Completion (Actual): August 8, 2024

Study Registration Dates

• First Submitted: December 10, 2020
• First Submitted That Met QC Criteria: January 12, 2021
• First Posted (Actual): January 15, 2021

Study Record Updates

• Last Update Posted (Actual): June 29, 2025
• Last Update Submitted That Met QC Criteria: June 25, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19
• Other Study ID Numbers: 20RM056

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No